LimFlow, developer of minimally-invasive technology for the treatment of end-stage critical limb ischaemia (CLI), has announced the expansion of the company’s senior management team. Sophie Humbert has been appointed to the role of chief operating officer (COO) and Thomas Engels, III, has assumed the role of vice president of clinical affairs. The Paris, France-based company also announced the opening of its first US office in Silicon Valley, USA.
Prior to joining LimFlow, Humbert was the COO of Arterial Remodeling Technologies (Terumo). Previously, Humbert was CEO at CermaVein, where she led the company through CE marking and to commercialisation in several markets. Humbert holds a PhD in Pharmaceutical Sciences from the University of Geneva, Geneva, Switzeland, a Master’s degree in Management from EM Lyon, Lyon, France and a Pharmaceutical doctorate from the University Claude Bernard in Lyon, France.
Prior to joining LimFlow, Engels was vice president of clinical affairs for Claret Medical, Micell Technologies and CardioKinetix. Previously, Thomas was director of clinical research for 10 years at Abbott Vascular, where he managed its global portfolio of interventional cardiology studies. He holds a BS from Louisiana State University, Baton Rouge, USA, and MBA degrees from the Columbia Business School and the Haas School of Business at University of California, Berkeley, USA.
Dan Rose, chief executive officer of LimFlow, says, “We are also excited to expand our operation into the USA to support our ongoing US clinical work.”
In April, the US Food and Drug Administration (FDA) approved the company’s Investigational Device Exemption for a feasibility study of the LimFlow Percutaneous Deep Vein Arterialisation (pDVA) System.